Please login to the form below

Not currently logged in

Deal Watch table for December 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during December 2014.

For an indepth analysis of these deals, read 'Pharma deals during December 2014'

Licensor acquired / licensee acquirer

Product / technology

Deal type

Headline ($m)

Cubist / Merck & Co
Portfolio of marketed and late stage antibiotics
Company acquisition
Avanir Pharmaceuticals / Otsuka Pharmaceutical
Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect
Company acquisition
*Astellas/ J&J
ASP015K, an oral JAK inhibitor for RA (p3)Exercise of opt-out/ termination**945
Macrogenics / J&JMGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical)Licence700
Cytokinetics / Astellas Pharma
CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1)
Expansion of collaboration/ amended agreement
Halozyme Therapeutics / J&J
ENHANZE rHuPH20 delivery technology for up to 5 targets
Collaboration, licence
Opko Health / Pfizer
Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3)
Adocia / Eli Lilly
BioChaperone Lispro (ultra-rapid insulin) based on BioChaperone technology (p1b)
Licence, collaboration
Dutalys / Roche
DutaMab technology for development of fully human, bispecific antibodies
Company acquisition
PneumRx / BTG
Portfolio of medical devices for interventional pulmonology inc RePneu Coil
Company acquisition
***GeNeuro / Servier
GNbAC1, mab to inhibit progression of MS without suppressing the immune system (p2)
Collaboration, option to license + take equity stake
Zosano Pharma / Eli Lilly
ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2)
OncoEthix / Merck & Co
Lead product oral BET inhibitor, OTX015 for oncology indications (p1b)
Company acquisition
Evotec / Sanofi
R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists)
Exclusive negotiations to create 5-year strategic alliance
Array BioPharma / Oncothyreon
ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1)
Licence - amended agreement
Spark Therapeutics / Pfizer
Multiple haemophilia B gene therapy products (preclinical)
Gene therapy collaboration
Xencor / Novo Nordisk
XmAb technologies, inc bispecific and immune inhibitor technologies, for undisclosed target
Collaboration, licence
Phylogica / Genentech
Phylomer drug discovery platform for novel antibiotics
Research & licensing agreement
Boston Heart Diagnostics / Eurofins Scientific
Diagnostics tests for chronic conditions including cardiovascular diseases and diabetes
Company acquisition
Sevion Therapeutics / J&J
Spatially addressed antibody discovery platform
Research collaboration, options to license
††Ariad Pharmaceuticals / Otsuka Pharmaceutical
Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph+ALL (JP NDA)
Co-development and commercialisation agreement


All deals global unless otherwise stated:

* ex Japan
** original deal headline value
***ex US, JP
† If Oncothyreon is acquired with 3 years of effective date, Array eligible for up to $280m milestones
†† JP + 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph+ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia)

The Deal Watch table is compiled by Medius Associates

8th January 2015

The Deal Watch table is compiled by Medius Associates

8th January 2015

From: Research, Sales



Career advice

No results were found

Subscribe to our email news alerts


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...